153 related articles for article (PubMed ID: 24171174)
21. Identification of novel genes associated with a poor prognosis in pancreatic ductal adenocarcinoma via a bioinformatics analysis.
Zhou J; Hui X; Mao Y; Fan L
Biosci Rep; 2019 Aug; 39(8):. PubMed ID: 31311829
[TBL] [Abstract][Full Text] [Related]
22. MicroRNA in pancreatic adenocarcinoma: predictive/prognostic biomarkers or therapeutic targets?
Brunetti O; Russo A; Scarpa A; Santini D; Reni M; Bittoni A; Azzariti A; Aprile G; Delcuratolo S; Signorile M; Gnoni A; Palermo L; Lorusso V; Cascinu S; Silvestris N
Oncotarget; 2015 Sep; 6(27):23323-41. PubMed ID: 26259238
[TBL] [Abstract][Full Text] [Related]
23. A six-gene signature predicts survival of patients with localized pancreatic ductal adenocarcinoma.
Stratford JK; Bentrem DJ; Anderson JM; Fan C; Volmar KA; Marron JS; Routh ED; Caskey LS; Samuel JC; Der CJ; Thorne LB; Calvo BF; Kim HJ; Talamonti MS; Iacobuzio-Donahue CA; Hollingsworth MA; Perou CM; Yeh JJ
PLoS Med; 2010 Jul; 7(7):e1000307. PubMed ID: 20644708
[TBL] [Abstract][Full Text] [Related]
24. SCNrank: spectral clustering for network-based ranking to reveal potential drug targets and its application in pancreatic ductal adenocarcinoma.
Liu E; Zhang ZZ; Cheng X; Liu X; Cheng L
BMC Med Genomics; 2020 Apr; 13(Suppl 5):50. PubMed ID: 32241274
[TBL] [Abstract][Full Text] [Related]
25. EYA4 functions as tumor suppressor gene and prognostic marker in pancreatic ductal adenocarcinoma through β-catenin/ID2 pathway.
Mo SJ; Liu X; Hao XY; Chen W; Zhang KS; Cai JP; Lai JM; Liang LJ; Yin XY
Cancer Lett; 2016 Oct; 380(2):403-412. PubMed ID: 27378242
[TBL] [Abstract][Full Text] [Related]
26. Increased CDC20 expression is associated with pancreatic ductal adenocarcinoma differentiation and progression.
Chang DZ; Ma Y; Ji B; Liu Y; Hwu P; Abbruzzese JL; Logsdon C; Wang H
J Hematol Oncol; 2012 Apr; 5():15. PubMed ID: 22475564
[TBL] [Abstract][Full Text] [Related]
27. Integration of mRNA and protein expression data for the identification of potential biomarkers associated with pancreatic ductal adenocarcinoma.
Akrami S; Tahmasebi A; Moghadam A; Ramezani A; Niazi A
Comput Biol Med; 2023 May; 157():106529. PubMed ID: 36921457
[TBL] [Abstract][Full Text] [Related]
28. Weighted gene co-expression network analysis reveals key genes involved in pancreatic ductal adenocarcinoma development.
Giulietti M; Occhipinti G; Principato G; Piva F
Cell Oncol (Dordr); 2016 Aug; 39(4):379-88. PubMed ID: 27240826
[TBL] [Abstract][Full Text] [Related]
29. Downregulation of RPL15 may predict poor survival and associate with tumor progression in pancreatic ductal adenocarcinoma.
Yan TT; Fu XL; Li J; Bian YN; Liu DJ; Hua R; Ren LL; Li CT; Sun YW; Chen HY; Fang JY; Hong J
Oncotarget; 2015 Nov; 6(35):37028-42. PubMed ID: 26498693
[TBL] [Abstract][Full Text] [Related]
30. Cystatin F as a key family 2 cystatin subunit and prognostic biomarker for early‑stage pancreatic ductal adenocarcinoma.
Yang C; Yu T; Liu Z; Ye X; Liao X; Wang X; Han C; Zhu G; Qin W; Peng T
Oncol Rep; 2019 Jul; 42(1):79-90. PubMed ID: 31059105
[TBL] [Abstract][Full Text] [Related]
31. Short report - Lethal and aggressive pancreatic cancer: molecular pathogenesis, cellular heterogeneity, and biomarkers of pancreatic ductal adenocarcinoma.
Kannan S; Shaik Syed Ali P; Sheeza A
Eur Rev Med Pharmacol Sci; 2022 Feb; 26(3):1017-1019. PubMed ID: 35179767
[TBL] [Abstract][Full Text] [Related]
32. HIF-2α regulates non-canonical glutamine metabolism via activation of PI3K/mTORC2 pathway in human pancreatic ductal adenocarcinoma.
Li W; Chen C; Zhao X; Ye H; Zhao Y; Fu Z; Pan W; Zheng S; Wei L; Nong T; Li Z; Chen R
J Cell Mol Med; 2017 Nov; 21(11):2896-2908. PubMed ID: 28544376
[TBL] [Abstract][Full Text] [Related]
33. Dipeptidyl peptidase like 6 promoter methylation is a potential prognostic biomarker for pancreatic ductal adenocarcinoma.
Zhao X; Cao D; Ren Z; Liu Z; Lv S; Zhu J; Li L; Lang R; He Q
Biosci Rep; 2020 Jul; 40(7):. PubMed ID: 32701143
[TBL] [Abstract][Full Text] [Related]
34. Aspartate β-hydroxylase promotes pancreatic ductal adenocarcinoma metastasis through activation of SRC signaling pathway.
Ogawa K; Lin Q; Li L; Bai X; Chen X; Chen H; Kong R; Wang Y; Zhu H; He F; Xu Q; Liu L; Li M; Zhang S; Nagaoka K; Carlson R; Safran H; Charpentier K; Sun B; Wands J; Dong X
J Hematol Oncol; 2019 Dec; 12(1):144. PubMed ID: 31888763
[TBL] [Abstract][Full Text] [Related]
35. Alteration of tumor-associated macrophage subtypes mediated by KRT6A in pancreatic ductal adenocarcinoma.
Zhang J; Sun H; Liu S; Huang W; Gu J; Zhao Z; Qin H; Luo L; Yang J; Fang Y; Ge J; Ni B; Wang H
Aging (Albany NY); 2020 Nov; 12(22):23217-23232. PubMed ID: 33221741
[TBL] [Abstract][Full Text] [Related]
36. A novel hotspot and rare somatic mutation p.A138V, at TP53 is associated with poor survival of pancreatic ductal and periampullary adenocarcinoma patients.
Saha G; Singh R; Mandal A; Das S; Chattopadhyay E; Panja P; Roy P; DeSarkar N; Gulati S; Ghatak S; Ghosh S; Banerjee S; Roy B; Ghosh S; Chaudhuri D; Arora N; Biswas NK; Sikdar N
Mol Med; 2020 Jun; 26(1):59. PubMed ID: 32552660
[TBL] [Abstract][Full Text] [Related]
37. Phosphoglycerate Mutase 1 (PGAM1) Promotes Pancreatic Ductal Adenocarcinoma (PDAC) Metastasis by Acting as a Novel Downstream Target of the PI3K/Akt/mTOR Pathway.
Liu X; Tan X; Liu P; Wu Y; Qian S; Zhang X
Oncol Res; 2018 Aug; 26(7):1123-1131. PubMed ID: 29386088
[TBL] [Abstract][Full Text] [Related]
38. CXCR4--A Prognostic and Clinicopathological Biomarker for Pancreatic Ductal Adenocarcinoma: A Meta-Analysis.
Krieg A; Riemer JC; Telan LA; Gabbert HE; Knoefel WT
PLoS One; 2015; 10(6):e0130192. PubMed ID: 26091099
[TBL] [Abstract][Full Text] [Related]
39. Desmogleins as prognostic biomarkers in resected pancreatic ductal adenocarcinoma.
Ormanns S; Altendorf-Hofmann A; Jackstadt R; Horst D; Assmann G; Zhao Y; Bruns C; Kirchner T; Knösel T
Br J Cancer; 2015 Nov; 113(10):1460-6. PubMed ID: 26469831
[TBL] [Abstract][Full Text] [Related]
40. Global microRNA expression profiling of microdissected tissues identifies miR-135b as a novel biomarker for pancreatic ductal adenocarcinoma.
Munding JB; Adai AT; Maghnouj A; Urbanik A; Zöllner H; Liffers ST; Chromik AM; Uhl W; Szafranska-Schwarzbach AE; Tannapfel A; Hahn SA
Int J Cancer; 2012 Jul; 131(2):E86-95. PubMed ID: 21953293
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
